Claims

1. Use of a pharmaceutical or dermatological composition in the manufacture of a medicament for the treatment of disease and/or pathologies selected from the group comprising fibrosis, retinal detachment, and/or treatment of age-related macular degeneration, dry age-related macular degeneration, wet age-related macular degeneration, epidermolysis bullosa, periodontal diseases, diseases of the buccal mucous membrane, burns, degenerative diseases,, lesions of the respiratory system, wherein said pharmaceutical or dermatological composition comprising

- a biocompatible polymer of the general formula (I) below

AaXxYy (I)

in which:

A represents a monomer, which is glucose

X represents an R_1COOR_2 or $–R_9(C=O)R_{10}$ group,

Y represents an O or N-sulfonate group complying with one of the following formulae: $–R_3OSO_3R_4$, $-R_5NSO_3R_6$, $R_7SO_3R_8$ in which:

R_1, R_3, R_5 and R_9 independently represent an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which optionally contains one or more aromatic cycles with the exception of benzylamine and benzylamine sulfonate, R_2, R_4, R_6 and R_8 independently represent a hydrogen atom or a cation,

R_7 and R_{10} independently represent a bond, an aliphatic hydrocarbon chain, optionally branched and/or unsaturated,

a represents the number of monomers,

x represents the rate of substitution of the monomers A by the groups X, y represents the rate of substitution of the monomers A by the groups Y, and

- hyaluronic acid.

2. A method for hydrating tissue and/or mucous membrane, and/or improving aging skin using a dermatological composition, wherein said dermatological composition comprises

- a biocompatible polymer of the general formula (I) below

AaXxYy (I)

in which:

A represents a monomer, which is glucose

X represents an R_1COOR_2 or $–R_9(C=O)R_{10}$ group,

Y represents an O or N-sulfonate group complying with one of the following formulae: $–R_3OSO_3R_4$, $-R_5NSO_3R_6$, $R_7SO_3R_8$ in which:

R_1, R_3, R_5 and R_9 independently represent an aliphatic hydrocarbon chain, optionally

branched and/or unsaturated, and which optionally contains one or more aromatic cycles with the exception of benzylamine and benzylamine sulfonate, R_2, R_4, R_6 and R_8 independently represent a hydrogen atom or a cation,
R_7 and R_{10} independently represent a bond, an aliphatic hydrocarbon chain, optionally branched and/or unsaturated,
a represents the number of monomers,
x represents the rate of substitution of the monomers A by the groups X, y represents the rate of substitution of the monomers A by the groups Y, and
- hyaluronic acid.

3. The method according to claim 2, wherein improving aging skin comprises increase cutaneous hydration, have an anti-wrinkle effect, improve the radiance and brightness of the skin, have uniform complexion, increase in texture, elasticity, coolness and/or tone of the skin.

4. The use of claim 1, or the method according to claims 2 or 3, wherein the number of monomer “a” is such that the mass of said polymers of formula (I) is greater than or equal to 3000 Daltons.

5. The use of claim 1 or 4, or the method according to any one of claims 2 to 4, wherein the rate of substitution “x” is between 10 and 150%.

6. The use of any one of claims 1, 4 to 5, or the method according to any one of claims 2 to 5, wherein the rate of substitution “y” is between 10 and 170%.

7. The use of any one of claims 1, 4 to 6, or the method according to any one of claims 2 to 6, characterized in that the radical R is selected from a linear or branched alkyl, allyl or aryl group.

8. The use of any one of claims 1, 4 to 7, or the method according to any one of claims 2 to 7, wherein said biocompatible polymer further comprises chemical functional groups Z which are different from X and Y and are capable of providing said polymer with additional biological or physicochemical properties.

9. The use of claim 8, or the method according to claim 8, wherein the rate of substitution “z” of all the monomers A, by the groups Z, is between 1 and 50%.

10. The use of claims 8 or 9, or the method according to claim 8 or 9, wherein the group Z is a substance capable of providing said polymers with an improved solubility or lipophilicity.

11. The use of claim 10, or the method according to claim 10, wherein the groups Z are identical or different and are selected from the group comprising amino acids, fatty acids, fatty alcohols, ceramides, or derivatives thereof, or indeed addressing nucleotide sequences.